ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
MyeChild-01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia – Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy
Protocol ID
RG_14-088 (MyeChild-01)
Condition/s
Acute Myeloid Leukaemia (AML)
Diagnosis Stage
New diagnosis
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
University of Birmingham
Collaborators
Assistance Publique - Hôpitaux de Paris
Cancer Research UK
National Cancer Institute, France
Pfizer
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 18 years
International registry ID's
NCT02724163
Back to Registry
Study Title MyeChild-01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia – Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy
Protocol ID RG_14-088 (MyeChild-01)
Disease (Sub Disease) Acute Myeloid Leukaemia (AML)
Diagnosis Stage New diagnosis
Sponsor Australian and New Zealand Children's Haematology Oncology Group/ University of Birmingham
Collaborators Assistance Publique - Hôpitaux de Paris/ Cancer Research UK/ National Cancer Institute, France/ Pfizer
Links https://clinicaltrials.gov/ct2/show/NCT02724163
Trial Status Closed to Recruitment
Trial Open Date 04/07/2018
Study Type Treatment
Phase Phase 3
Age Eligibility up to 18 years
International registry ID's NCT02724163

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168